

**Popis novih lijekova za koje je odobrenje dala Europska komisija od 1.8.2016. do 31.8.2016. godine/The list of new medicinal products authorised by the European Commission in August 2016**

<b>Redni broj/No.</b>	<b>Naziv lijeka/Name</b>	<b>Naziv djelatne tvari/Active Substance</b>	<b>Broj odobrenja EK/EC Authorisation number</b>	<b>ATK/ATC</b>
1.	Aerivio Spiromax	salmeterol / fluticasone propionate	EU/1/16/1122	R03AK06
2.	Airexar Spiromax	salmeterol / fluticasone propionate	EU/1/16/1123	R03AK06
3.	Atazanavir Mylan	atazanavir	EU/1/16/1091	J05AE08
4.	Cinquaero	reslizumab	EU/1/16/1125	R03DX08
5.	Kispplx	lenvatinib	EU/1/16/1128	L01XE29
6.	Nordimet	methotrexate	EU/1/16/1124	L01BA01
7.	Zalmoxis *	allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor ( $\Delta$ LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)	EU/1/16/1121	L01

\* lijek u EU ima "orphan" status/medicinal product with "orphan" designation